Safety and efficacy of elagolix (with and without add-back therapy) for the treatment of heavy menstrual bleeding associated with uterine leiomyomas: a systematic review and meta-analysis

Middle East Fertility Society Journal

Table 3 Study demographics and baseline clinical characteristics

Study	NCT no.	Elagolix dosage	Age (mean years)	BMI*	Menstrual blood loss/ ml	Hemoglobin levels/ gdL-1	Uterine volume /cm³
Archer	NCT01441635	300 BD	41.6/42.6/41.6	28.3/29.0/29.6	334/206/266	11.0/11.3/10.3	490/576/659
Carr	NCT01817530	300 BD	44.0/43.0/44.0	30.0/30.0/30.0	238/265/296	11.1/10.5/10.4	627/680/816
Carr	NCT01817530	600 QD	43.0/42.0/43.0	30.7/31.0/31.0	222/208/247	10.9/10.7/11.0	570/577/582
Elaris UF-1	NCT02654054	300 BD	41.6/42.6/42.6	33.8/33.4/33.3	255/249/238	11.0/10.6/11.1	478/500/475
Elaris UF-2	NCT02691494	300 BD	42.5/42.2/42.5	33.8/34.5/33.2	254/225/229	11.0/11.0/11.1	550/537/496